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Summary An enzyme-linked immunosorbent assay (ELISA) using monoclonal and polyclonal antibodies
against t-PA was used to measure the concentration of tissue-type plasminogen activator (t-PA) in plasma
from 34 healthy donors and 92 breast cancer patients with a varying extent of disease. The mean value of t-PA
in plasma for the healthy donors was 2.4 ± 2.1 ng ml'- (s.d.). The mean value for the breast cancer patients
was 5.3 ± 4.3 ng ml '. This increase was statistically significant at the 1% level. There was a positive
correlation between the mean t-PA plasma concentration and the extent of disease in different groups of
patients. Taking 5.0 ng ml-l as cut-off point, about 40% of the patients were positive, and 6% of the normal
controls were false positive. Twenty-five per cent of the patients in complete remission, 28% of the patients
with minimal tumour burden, 60% of the patients with moderate tumour burden, and 90% of the patients
with massive tumour burden were positive. It is possible that the patients with an elevated plasma t-PA
represent a group with a particularly bad prognosis.
Proteolysis caused by activation of plasminogen to plasmin
plays an important role in many biological processes. In
mammals there are two types of plasminogen activators: the
urokinase-type (u-PA) and the tissue-type (t-PA). Both are
serine proteases, but they differ in M, (50,000 and 70,000
respectively), immunological reactivity and amino acid
sequence. The two activators are produced by different cell
types in the organism and seem to be involved in different
functions. u-PA is supposed to be a key enzyme in break-
down of extracellular matrix proteins during tissue destruc-
tion in a variety of normal and pathological conditions,
including the invasive growth of cancer cells, while t-PA is
involved in thrombolysis (for a review see Dan0 et al., 1985).
Both u-PA and t-PA are found in blood (Granelli-Piperno
& Reich, 1978; Astedt, 1978; Rijken et al., 1980; Bergsdorf et
al., 1983; Holvoet et al., 1985). We have previously developed
polyclonal and monoclonal antibodies against u-PA and t-PA
and by using a combination of these antibodies we have
developed ELISAs for the measurement of u-PA (Gr0ndahl-
Hansen et al., 1988) and t-PA (Gr0ndahl-Hansen &
Ottevanger, 1989) in plasma.
We have previously measured the concentration of plasma
u-PA in a material of breast cancer patients (Gr0ndahl-
Hansen et al., 1988) and we found that the concentration of
u-PA was positively correlated with tumour burden. We now
report results of t-PA concentrations in the same patient
material.
Materials and methods
Patients and healthy controls
The human material used in this study was the same used in
a previously study for determination of the u-PA concentra-
tion in plasma and included 34 healthy controls (group H)
and 92 patients who had previously had surgery for breast
cancer or having advanced breast cancer.
The breast cancer patients were primarily divided into two
main groups, A and B, according to the criteria of WHO
(1979). Group A consisted of 44 patients with no clinical
signs of breast cancer at the time of the blood test, and
included (1) 20 patients who had had radical surgery for
breast cancer and (2) 24 patients brought to complete remis-
sion by surgery combined with chemotherapy, hormone
therapy and/or radiotherapy.
Group B consisted of 48 patients with clinical signs of
breast cancer. These patients were further subdivided into
three groups according to the tumour burden at the time of
examination (see Grondahl-Hansen et al. (1988) for
classification). Group B, consisted of 18 patients with
minimal, group B2 of 20 with moderate and group B3 of 10
with a massive tumour burden.
The sex and age distributions for the various groups are
listed in Table I. All patients were outpatients and none
presented any clinical signs of infection. For patients who
had had surgery, the operation preceded the blood test by 25
days to 13 years (median 2 years). None of the patients had
had radiotherapy or hormone treatment within a period of I
month preceding the blood test, except one patient who was
currently being treated with irradiation of the skull. Some of
the patients were currently being treated with one or more of
the following drugs: cyclophosphamide, doxorubicin, 4-
epidoxorubicin (Adriamycin; Farmitalia), methotrexate, 5-
fluorouracil and vindesine. These included 22 patients in
group A, II in group B1, 17 in group B2 and nine in B3.
Human plasma
For preparation of human plasma, nine volumes of blood
obtained by venepuncture were collected in tubes containing
one volume of 0.13 M sodium citrate. The tubes were
immediately placed on ice and centrifuged at 2,000 g for
Omin. The plasma was stored at - 2OC until analysis.
Tissue-type plasminogen activator
Human t-PA was prepared as described (Gr0ndahl-Hansen et
al., 1985) from culture medium from the Bowes melanoma
cell line by affinity chromatography on a Sepharose column
coupled with a monoclonal antibody against t-PA (anti-t-PA
clone 1). The protein concentration of this preparation was
determined by the method of Lowry. When comparing our
t-PA standard with the international t-PA standard (Lot
83/517 obtained from the National Institute for Biological
Standards and Control, Holly Hill, London) in the t-PA
ELISA 1 ng corresponds to 0.44 IU.
ELISA for t-PA in plasma
The t-PA ELISA described by us (Gr0ndahl-Hansen &
Ottevanger, 1989) was used. Briefly, microtitre plates were
coated with a monoclonal antibodv a2ainst t-PA, blocked
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Table I Plasma t-PA concentration in normal donors and breast cancer patients
Sex Age (years) Plasma t-PA (ngml')
Group n Females Males Mean Range Mean s.d. Range
H 34 22 12 40 25-54 2.4 2.1 0.3-11.0
H (female) 22 22 0 40 25-54 2.3 2.3 0.3-11.0
H (male) 12 0 12 39 33-52 2.5 1.4 0.4- 4.7
H (<40 years) 21 12 9 35 25-40 2.5 2.4 0.3-11.0
H (>40 years) 13 10 3 48 41-54 2.2 1.4 0.4- 5.6
A + B 92 92 0 53 15-76 5.3 4.3 0.0-21.4
A 44 44 0 52 15-75 3.8 2.5 0.0-10.6
B 48 48 0 55 36-76 6.7 5.1 1.2-21.4
B, 18 18 0 56 36-76 4.4 3.7 1.2-17.1
B2 20 20 0 56 41 -75 5.6 2.7 1.3-12.3
B3 10 10 0 51 41-60 13.0 6.2 4.6-21.4
Group H consists ofnormal donors, while the othergroups are breast cancerpatients in remission (A) or
withclinical signsofdisease(B), thelattergroupbeingsubdivided intothree(B1,B2,B3)accordingtotumour
burden.
with newborn calf serum, and incubated with plasma sample.
The bound t-PA was quantitated with biotinylated polyclonal
antibodies against t-PA followed by avidin-peroxidase.
This ELISA has a detection limit of about 10 pg t-PA per
100 gil, and has a linear dose-response up to at least 600 pg
per well. It detects complexes of t-PA and plasminogen
activator inhibitor type-l (PAI-1) and does not cross-react
with structurally related proteins, including u-PA and plas-
minogen, or with t-PA from other species, such as rabbit,
horse, swine and calf (Gr0ndahl-Hansen & Ottevanger,
1989).
donors below 40 years of age was compared to those over 40
years (see Table I).
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Results
t-PA in plasma ofhealthy donors and breast cancer patients
The ELISA was used to determine the t-PA concentration in
the plasma from 34 healthy donors and 92 breast cancer
patients (Figure 1 and Table I). The mean concentration of
t-PA in plasma from healthy donors were 2.4 ± 2.1 ng ml-',
while the mean value for the breast cancer patients was
slightly higher than that of the healthy controls
(5.3 ± 4.3 ng ml-'). This increase in the mean value was
statistically significant at the 1% level, as evaluated by the
Wilcoxon rank sum test.
The mean value for the patients in remission (A) was
significantly different from that of the control group (at the
1% level); for the group B patients, the mean value was also
significantly increased (at the 1% level) compared to that of
the healthy donors. The mean values for groups B,, B2 and
B3 were all significantly higher than that of the control group
at the 1% level.
There was a positive correlation between the mean t-PA
plasma concentration and the extent of disease in different
groups of patients. Taking 5.0 ng ml-' as cut-off point, about
40% of the patients were positive and 6% of the normal
controls were false positive. Twenty-five per cent of the
patients in complete remission, 28% of the patients with
minimal tumour burden, 60% of the patients with moderate
tumour burden and 90% of the patients with massive tumour
burden were positive.
When comparing the results of the previous determinations
of u-PA concentration on the same material, with the t-PA
measurements reported here, we find that the correlation
with tumour burden is stronger for t-PA than for u-PA.
Nevertheless, a high concentration of t-PA could be observed
together with a low concentration of u-PA, and vice versa.
Using 1.5 ng ml-' as the cut-off point for u-PA, and
5.0 ng ml-' as the cut-off point for t-PA we obtain the
following percentages of positive samples (positive for one or
both of the plasminogen activators): H, 6%; A, 34%; BI,
44%; B2, 75%; and B3, 90%.
The control group showed no significant difference
between plasma t-PA in female and male donors and there
was no significant age dependency when the group of normal
15
E
Q-
0)
10
0
@0 00
. 0
0 0
0
0
0
0
0
0
0
00
00
000
00
00000
000000
@0
@0000
@000
0 0
0
0
0
000
00
00
0
00
000 0*00
0000
@000@0
000000 o_O"
0
000
0
0
0
0
00
S"- 0000 @000
00
*000
000000
0
0
000
0
000
0 0
00
00
0
0000
0
00
*- 00 00
0
00 00
0
0
0
0
H A B B, B2 B3
Figure 1 t-PA concentration in plasma from normal donors and
patients with breast cancer determined by ELISA. Blood samples
were collected by venepucture from 34 healthy donors (H) and
from 92 breast cancer patients. The patients were divided into a
group of 44 with complete remission (A), and 48 with clinically
detectable disease (B). The patients with detectable disease were
further divided into three groups according to the extent of
disease (tumour burden): 18 patients with minimal (B,), 20 with
moderate (B2) and 10 with massive (B3) disease. The t-PA concen-
tration of plasma was measured by ELISA.
Discussion
The mean t-PA concentration in plasma of normal donors of
2.4 ± 2.1 ng ml-' (range 0.3-I1 ng ml-') obtained in this
study is in agreement with that obtained in an earlier study
(Gr0ndahl-Hansen & Ottevanger, 1989) and slightly lower414 J. GR0NDAHL-HANSEN et al.
than that reported by others (Bergsdorf et al., 1983; Holvoet
et al., 1985). The majority of breast cancer patients showed
no increased plasma t-PA values, but above 40% of the
patients had plasma t-PA concentrations above the cut-off
point (5.0 ngml-'). Patients with increased t-PA values were
found in all the groups to which the patients were allocated
according to the extent of their actual disease, but the
relative number of patients with high levels increased with
the extent of the disease, constituting 90% of the patients
allocated to the group with massive tumour burden.
Similarly, the mean value of plasma t-PA was significantly
increased for all breast cancer patients, and increased with
the tumour burden. The different mean t-PA values for the
various groups of patients do not appear to be due to age
differences as evaluated by the data shown in Table I. It
therefore appears likely that the different tumour burden is
the main reason for the different mean t-PA values in the
different groups, although further prospective studies are
needed to exclude an effect of the other parameters.
When comparing the results of the previous determinations
of u-PA concentration on the same material (Gr0ndahl-
Hansen et al., 1988) with the t-PA measurements reported
here, we see that the correlation with tumour burden is
stronger for t-PA than for u-PA. The plasma t-PA level
might thus, from a diagnostic point of view, be of more value
in breast cancer than the plasma u-PA level. In contrast to
the present findings, Colombi et al. (1984) found a very
decreased plasminogen activator activity in plasma from
patients with breast cancer. Colombi et al. (1984) used a
semi-quantitative zymographic method, and the influence of
inhibitors of the plasminogen activators cannot be excluded.
The type of plasminogen activator measured was not deter-
mined in that study.
Several studies have been reported on the content of plas-
minogen activators in human breast tumours (Colombi et al.,
1984; Evers et al., 1982; Tissot et al., 1984; Layer et al., 1987;
Duffy et al., 1988) and elevated concentrations have been
reported mainly to be due to an increase in the u-PA content
(Evers et al., 1982; Layer et al., 1987). Duffy et al. (1988)
measured the t-PA concentration in breast tumour lysates
and found that a high content of t-PA was associated with a
good prognosis. In apparent contrast to this, we find a
positive correlation between tumour burden and t-PA in
plasma. However, Duffy et al. (1988) measured on lysates of
primary tumours, and we measured on plasma from patients
with a median of 2 years after surgery.
The reason for the increase in plasma concentration of
t-PA in breast cancer patients is not known, and the origin of
the t-PA remains to be determined. Immunohistochemical
studies of the localisation of the different plasminogen
activators in human breast tumours (Clavel et al., 1986) have
indicated that t-PA was localised to secretions of mammary
glands in benign lesions and that u-PA and t-PA had a
cellular labelling in invasive territories of carcinomas. The
study by Duffy et al. (1988), in which a high content of t-PA
in the tumours is correlated with a better prognosis, argues
against the tumours as the source of the elevated amounts of
plasma t-PA found in the present study. A possible source,
beside the tumours, is the endothelial cells in the veins. It is,
however, also possible that the elevated plasma t-PA concen-
trations are caused by a decreased catabolism of t-PA in the
liver.
Because of the supposed involvement of plasminogen
activation in tissue destruction and invasiveness, it is possible
that breast cancer patients with elevated plasma t-PA or
u-PA represent groups of patients with a particularly bad
prognosis, and that the measuring of plasminogen activator
concentrations in plasma might therefore have a clinical
value. A clarification of this point requires prospective
studies.
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